Novel ECG Measures and Risk of Sudden Cardiac Death
Novel ECG Measures and Risk of Sudden Cardiac Death
批准号:
8595389
负责人:
Larisa Gennadievna Tereshchenko
金额:
$40.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-01 至 2013-12-14
关键词:
AccountingAdultAgeAtherosclerosisAutopsyBiometryBundle-Branch BlockCardiacCardiologyCardiovascular systemCause of DeathCellsCessation of lifeCicatrixClassificationClinicalCohort StudiesCommunitiesComputer softwareCoronary heart diseaseCouplingDepressed moodDevelopmentEchocardiographyElectrocardiogramElectrophysiology (science)EpidemiologyFrequenciesFunctional disorderFundingFutureGenderGeneral PopulationGenesGeneticHealthHeartHeart DiseasesHeart RateHuman GeneticsInterventionLaboratoriesLeadLeftLeft Ventricular HypertrophyMeasuresMetricMolecularNatural HistoryPathologicPatientsPersonsPhenotypePhysiologicalPopulationPopulations at RiskPreventionPropertyPublic HealthRaceRestRiskRisk EstimateRisk FactorsRisk MarkerSourceStratificationTechniquesTestingUnited States National Institutes of HealthVariantVentricularVentricular ArrhythmiaVentricular FibrillationVisitbasecase controlcohortdigitalfollow-upgenome wide association studyheart cellheart disease riskhigh riskimprovedmortalitynotch proteinnovelpreventprospectivepublic health relevancerepositorysudden cardiac deathtooltrait
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Sudden cardiac death (SCD) is a major public health concern, accounting for 400,000 deaths in the US each year. Clinical and autopsy studies have consistently demonstrated a predominant, common pathophysiology in Western populations, showing that the most common electro-physiologic mechanism for SCD is ventricular fibrillation (VF) and the most common pathologic substrate is coronary heart disease (CHD). In about half of SCD cases, death is the first clinical manifestation of CHD. Yet risk factors of SCD early in the natural history of conditions predisposing SCD have not been fully identified, and SCD risk stratification strategy in general population has not been developed. ECG is easy available, non-expensive and non- invasive tool, which carries valuable information on electrophysiological properties of the heart. However, traditional analysis of ECG includes very limited assessment of the arrhythmogenic substrate. Recently we developed novel 12-lead ECG SCD risk score, composed of parameters that measure (1) slow discontinued conduction, (2) temporal repolarization lability, and (3) adverse electrical remodeling. Preliminary gender-, race-, and age-matched case-control analysis of the Atherosclerosis In Community (ARIC) study showed a total continuous net reclassification improvement of 86.0% as compared to the Framingham risk score alone. We hypothesize that (1) the "SCD ECG risk score", comprised of the mechanistic ECG markers of arrhythmogenic substrate derived in the resting 12-lead ECG analysis accurately stratify persons into high-, intermediate- and low-risk groups and improve classification in comparison to the risk stratification on the basis of traditional CHD risk factor; (2) heritable factors of the novel ECG phenotype are associated with the increased SCD risk. This application bridges a critical gap between understanding of the SCD mechanisms and SCD risk stratification in a general population. We will leverage 2 unique large NIH-funded prospective community-dwelling GWAS cohorts with an available digital 12-lead ECG repository: ARIC and CHS. Baseline digital 12-lead ECG will be analyzed by customized Matlab software in PI's laboratory. The SCD ECG risk score will be developed in ARIC and validated in the CHS cohort. Net reclassification improvement will be assessed. Longitudinal changes in studied ECG parameters over 20 years of follow-up will be evaluated as predictors of cardiac structural and functional phenotype, assessed by echocardiography at the 5th ARIC visit. Our study will identify genes, associated with specific ECG traits, which will lead to novel targets fo treatments and in the future will enable SCD prevention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel ECG Measures and Risk of Sudden Cardiac Death
-
批准号:8825630
-
项目类别:
-
资助金额:$37.33万
-
财政年份:2013
-
负责人:Larisa Gennadievna Tereshchenko
-
依托单位:
海外基金